Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
A lot of them dont have the data. Toby wasnt here for a peptide injection, but Koniver advised him to try one on a future visit
Preclinical Research Context : Referenced in studies investigating CNS-relevant outcomes, such as neurogenesis and recovery-related endpoints (for research use only)
Out-of-spec pH (too acidic or too alkaline) accelerates hydrolysis of Asp-Pro and Asp-Gly bonds
Effectiveness Does it work
US$ 21.98
US$ 21.91
US$ 28.23
